maprotiline has been researched along with Premenstrual Syndrome in 1 studies
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.
Premenstrual Syndrome: A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eriksson, E | 1 |
| Hedberg, MA | 1 |
| Andersch, B | 1 |
| Sundblad, C | 1 |
1 trial available for maprotiline and Premenstrual Syndrome
| Article | Year |
|---|---|
The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
Topics: Double-Blind Method; Female; Humans; Maprotiline; Paroxetine; Placebos; Premenstrual Syndrome; Treat | 1995 |